The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 801–900 of 1,001
Koperniku, A., Garcia, A. A., & Mochly‐Rosen, D. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01577 · Cited by 26
Toward the Design of Ligands Selective for the C-Terminal Domain of TEADs
Liberelle, M., Toulotte, F., Renault, N., Gelin, M., Allemand, F., Melnyk, P., Guichou, J., & Cotelle, P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00075 · Cited by 25
Studies on enmetazobactam clarify mechanisms of widely used β-lactamase inhibitors
Lang, P. A., Raj, R., Tumber, A., Lohans, C. T., Rabe, P., Robinson, C. V., Brem, J., & Schofield, C. J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117310119 · Cited by 24
“, sulfonamide antibiotics (23)] and there is growing interest in covalently acting drugs (24, 25), sulfones are rare in drugs and, as far as we are aware, sulbactam and tazobactam are the only clinically approved sulfone-containing drugs working by covalent reaction with their targets (26–28).”
BackgroundNever Gonna Give You Up – Current Developments in Covalent Protein Kinase Inhibitors
Hillebrand, L., & Gehringer, M. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.435 · Cited by 25
Covalent inhibitors of bacterial peptidoglycan biosynthesis enzyme MurA with chloroacetamide warhead
Grabrijan, K., Hrast, M., Proj, M., Dolšak, A., Zdovc, I., Imre, T., Petri, L., Ábrányi‐Balogh, P., Keserű, G. M., & Gobec, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114752 · Cited by 27
Podoll, T., Pearson, P. G., Kaptein, A., Evarts, J., de Bruin, G., Hoek, M. E.-V., de Jong, A., van Lith, B., Sun, H., Byard, S. J., et al. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001116 · Cited by 28
Rosenker, C. J., Krenske, E. H., Houk, K. N., & Wipf, P. (2013) · Organic Letters · doi:10.1021/ol400094k · Cited by 23
Cheng, X., Li, L., Uttamchandani, M., & Yao, S. Q. (2014) · Organic Letters · doi:10.1021/ol500206w · Cited by 23
Maucher, I. V., Rühl, M., Kretschmer, S. B. M., Hofmann, B., Kuhn, B. R., Fettel, J., Vogel, A., Flügel, K., Manolikakes, G., Hellmuth, N., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.004 · Cited by 23
Gunasekaran, V. P., Nishi, K., Sivakumar, D., Sivaraman, T., & Ganeshan, M. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.09.019 · Cited by 23
Sameshima, T., Yamamoto, T., Sano, O., Sogabe, S., Igaki, S., Sakamoto, K., Ida, K., Gotou, M., Imaeda, Y., Sakamoto, J., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b00732 · Cited by 27
Covalent Kinase Inhibitors: An Overview
Gehringer, M. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_103 · Cited by 27
Profiling the proteome-wide selectivity of diverse electrophilesPreprint
Zanon, P. R. A., Yu, F., Musacchio, P. Z., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2021) · doi:10.33774/chemrxiv-2021-w7rss-v2 · Cited by 25
Aloui, M., Er-rajy, M., Imtara, H., Goudzal, A., Zarougui, S., fadili, M. E., Arthur, D. E., Mothana, R. A., Noman, O. M., Tarayrah, M., et al. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101911 · Cited by 24
“This necessitates a wider range of inhibitors with innovative structures and enhanced target-binding selectivity (Singh et al., 2011).”
Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1
Alboreggia, G., Udompholkul, P., Baggio, C., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00277 · Cited by 22
“success of covalent drugs targeting Cys in recent years 22,23,40 − 54 continues to drive drug discovery efforts toward the Cysteinome , 52 − 54 which is the target space that contains a druggable Cys residue.”
Auf Lysin zielende, kovalente Inhibitoren
Pettinger, J., Jones, K., & Cheeseman, M. D. (2017) · Angewandte Chemie · doi:10.1002/ange.201707630 · Cited by 22
Discovery and optimization of covalent Bcl-xL antagonists
Mukherjee, H., Su, N., Belmonte, M. A., Hargreaves, D., Patel, J. S., Tentarelli, S., Aquila, B. M., & Grimster, N. P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126682 · Cited by 23
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations
Lodola, A., Callegari, D., Scalvini, L., Rivara, S., & Mor, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_19 · Cited by 25
Generation of Highly Selective, Potent, and Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors
Rowlands, R. A., Chen, Q., Bouley, R. A., Avramova, L. V., Tesmer, J. J. G., & White, A. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01522 · Cited by 22
Truong, J. Q., George, A., & Holien, J. K. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00213a · Cited by 27
Inverse Drug Discovery identifies weak electrophiles affording protein conjugates
Kline, G. M., Nugroho, K., & Kelly, J. W. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102113 · Cited by 23
Relative Nuclease Resistance of a DNA Aptamer Covalently Conjugated to a Target Protein
Tabuchi, Y., Yang, J., & Taki, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147778 · Cited by 22
Meden, A., Knez, D., Brazzolotto, X., Modeste, F., Perdih, A., Pišlar, A. H., Zorman, M., Zorović, M., Denic, M., Pajk, S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115048 · Cited by 25
Technologies for Direct Detection of Covalent Protein–Drug Adducts
Mons, E., Kim, R. Q., & Mulder, M. P. C. (2023) · Pharmaceuticals · doi:10.3390/ph16040547 · Cited by 26
“Among the most prescribed drugs in the US, [1,2] are successful drugs that were later found to have a covalent binding mode (Figure A1A in Appendix A), including established pain killer/anti-inflammatory agent aspirin [3], β-lactam antibiotic penicillin [4], anticoagulant clopidogrel (Plavix) [5], and proton-pump inhi…”
BackgroundInfluentialLiu, F., Liu, C., Chai, Q., Zhao, C., Meng, H., Xia, X., Yao, T., & Zhang, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00977 · Cited by 22
Compain, G., Monsarrat, C., Blagojevic, J., Brillet, K., Dumas, P., Hammann, P., Kühn, L., Martiel, I., Engilberge, S., Oliéric, V., et al. (2024) · JACS Au · doi:10.1021/jacsau.3c00572 · Cited by 22
Field, J. J., Pera, B., Estévez‐Gallego, J., Calvo, E., Rodríguez‐Salarichs, J., Sáez-Calvo, G., Zuwerra, D., Jordi, M., Andreu, J. M., Prota, A. E., et al. (2017) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b00704 · Cited by 24
Characterization of covalent modifications of HDL apoproteins by endogenous oxidized phospholipids
Gao, D., & Podrez, E. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.11.012 · Cited by 25
Tjin, C. C., Otley, K. D., Baguley, T. D., Kurup, P. K., Xu, J., Nairn, A. C., Lombroso, P. J., & Ellman, J. A. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00486 · Cited by 22
DUckCov: a Dynamic Undocking‐Based Virtual Screening Protocol for Covalent Binders
Rachman, M. M., Scarpino, A., Bajusz, D., Pálfy, G., Vida, I., Perczel, A., Barril, X., & Keserű, G. M. (2019) · ChemMedChem · doi:10.1002/cmdc.201900078 · Cited by 23
Discovery of Irreversible p97 Inhibitors
Ding, R., Zhang, T., Wilson, D. J., Xie, J., Williams, J. M., Xu, Y., Ye, Y., & Chen, L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00144 · Cited by 22
Abis, G., Charles, R. L., Kopec, J., Yue, W. W., Atkinson, R. A., Bui, T. T. T., Lynham, S., Popova, S., Sun, Y., Fraternali, F., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0426-2 · Cited by 22
Grimsey, N. L., Savinainen, J. R., Attili, B. N. N. R., & Ahamed, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.10.004 · Cited by 22
Liu, H., Niu, D., Sjin, R. T. T., Dubrovskiy, A., Zhu, Z., McDonald, J. J., Fahnoe, K. C., Wang, Z., Munson, M., Scholte, A. A., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00601 · Cited by 22
Design and Mechanism of Tetrahydrothiophene-Based γ-Aminobutyric Acid Aminotransferase Inactivators
Le, H. V., Hawker, D. D., Wu, R., Doud, E. H., Widom, J. R., Sanishvili, R., Liu, D., Kelleher, N. L., & Silverman, R. B. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b01155 · Cited by 22
Pierce, E. N., Piyankarage, S. C., Dunlap, T. L., Litosh, V. A., Siklos, M. I., Wang, Y.-T., & Thatcher, G. R. J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00115 · Cited by 22
Covalent Targeting of Histidine Residues with Aryl Fluorosulfates: Application to Mcl-1 BH3 Mimetics
Alboreggia, G., Udompholkul, P., Atienza, E. L., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01541 · Cited by 21
“6,8 − 10,21,22,25 − 33 We and others have previously demonstrated that aryl fluorosulfates are very stable in aqueous media and even in vivo .”
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
Tao, H., Yang, B., Farhangian, A., Xu, K., Li, T., Zhang, Z., & Li, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02760 · Cited by 22
An mRNA Display Approach for Covalent Targeting of a Staphylococcus aureus Virulence Factor
Wang, S., Woods, E. C., Jo, J., Zhu, J., Hansel-Harris, A., Holcomb, M., Llanos, M. A., Pedowitz, N. J., Upadhyay, T., Bennett, J. M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c15713 · Cited by 22
Oxidative Stress in Antigen Processing and Presentation
Chang, Q., Zhang, Y., Liu, X., Miao, P., Pu, W., Liu, S., Zhang, J., Yuan, T., Shen, G., & Xie, N. (2025) · MedComm – Oncology · doi:10.1002/mog2.70020 · Cited by 27
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update
Roskoski, R. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107805 · Cited by 23
Li, L., Chen, N., Xia, D., Xu, S., Dai, W., Tong, Y., Wang, L., Jiang, Z., You, Q., & Xu, X. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.016 · Cited by 22
Rational design of thioamide peptides as selective inhibitors of cysteine protease cathepsin L
Phan, H. A. T., Giannakoulias, S. G., Barrett, T. M., Liu, C., & Petersson, E. J. (2021) · Chemical Science · doi:10.1039/d1sc00785h · Cited by 23
The NLRP3 Inflammasome in the Pathogenesis and Treatment of Alzheimer’s Disease
Golzari-Sorkheh, M., Brown, C. E., Weaver, D. F., & Reed, M. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210660 · Cited by 23
“Despite the associated risk of idiosyncratic toxicity and hypersensitivity associated with covalently binding drugs, many have previously been approved for human administration [162].”
Parenti, M. D., Naldi, M., Manoni, E., Fabini, E., Cederfelt, D., Talibov, V., Gressani, V., Güven, Ü., Grossi, V., Fasano, C., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114683 · Cited by 23
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Cheke, R. S., & Kharkar, P. S. (2023) · Drug Development Research · doi:10.1002/ddr.22132 · Cited by 26
“The development of “ targeted covalent drugs ” has made significant advancements in the clinical setting, particularly in the past 15 years (Ghosh et al., 2019; Lonsdale & Ward, 2018; Singh et al., 2011).”
BackgroundFitting of kinact and KI Values from Endpoint Pre-incubation IC50 Data
Mader, L. K., & Keillor, J. W. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00054 · Cited by 25
Yuan, B., Feng, Y., Ma, M., Duan, W., Wu, Y., Liu, J., Zhao, H., Yang, Z., Zhang, S., & Xin, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01284 · Cited by 21
Salicylanilide diethyl phosphates as cholinesterases inhibitors
Krátký, M., Štěpánková, Š., Vorčáková, K., & Vinšová, J. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.11.005 · Cited by 21
Rovira, C. (2013) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1153 · Cited by 22
Investigation of the electrophilic reactivity of the cytotoxic marine alkaloid discorhabdin B
Lam, C. F. C., Grkovic, T., Pearce, A. N., & Copp, B. R. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob07090a · Cited by 21
Francis, S., Laurieri, N., Nwokocha, C. R., & Delgoda, R. (2016) · Scientific Reports · doi:10.1038/srep26906 · Cited by 21
Bruno, S., Uliassi, E., Zaffagnini, M., Prati, F., Bergamini, C., Amorati, R., Paredi, G., Margiotta, M., Conti, P., Costi, M. P., et al. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12941 · Cited by 21
Xie, Y., Dahlin, J. L., Oakley, A. J., Casarotto, M. G., Philip G. Board, & Baell, J. B. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00318 · Cited by 25
Fritz, R. A., Alzate‐Morales, J. H., SPENCER, J. M., Mulholland, A. J., & van der Kamp, M. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00480 · Cited by 22
Khan, S., Bjij, I., Olotu, F. A., Agoni, C., Adeniji, E. A., & Soliman, M. E. S. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0304 · Cited by 23
Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases
Coughlin, Q., Hopper, A. T., Blanco, M.-J., Tirunagaru, V. G., Robichaud, A. J., & Doller, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01651 · Cited by 23
Opportunities and challenges for the development of covalent chemical immunomodulators
Backus, K. M., Cao, J. X., & Maddox, S. M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.050 · Cited by 21
Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury
Ali, S.-E., Waddington, J. C., Park, B. K., & Meng, X. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00275 · Cited by 22
Basagni, F., Rosini, M., & Decker, M. W. (2020) · ChemMedChem · doi:10.1002/cmdc.202000298 · Cited by 22
Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
Wang, Y., Chen, Z., Dai, M., Sun, P., Wang, C., Gao, Y., Zhao, H., Zeng, W., Shen, L., Mao, W., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.014 · Cited by 21
Sinha, S. H., Ahire, D. S., Wagh, S., Mullick, D., Sistla, R. K., Selvakumar, K., Caceres‐Cortes, J., Putlur, S. P., Mandlekar, S., & Johnson, B. M. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500256j · Cited by 21
Wen, W., Cao, H., Xu, Y., Ren, Y., Rao, L., Shao, X., Chen, H., Wu, L., Liu, J., Chen, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00336 · Cited by 20
Jung, Y., Noda, N., Takaya, J., Abo, M., Toh, K., Tajiri, K., Cui, C., Zhou, L., Sato, S., & Uesugi, M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00824 · Cited by 20
Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery
Zhao, Z., & Bourne, P. E. (2022) · Pharmaceuticals · doi:10.3390/ph15111322 · Cited by 19
“While significant progress has been made in the design and development of covalent kinase inhibitors, covalent‐inhibition‐induced potential toxicities still exist [21,38,39].”
BackgroundHCovDock: an efficient docking method for modeling covalent protein–ligand interactions
Wu, Q., & Huang, S. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac559 · Cited by 23
A red light-triggered chemical tool for sequence-specific alkylation of G-quadruplex and I-motif DNA
Cadoni, E., Paepe, L. D., Colpaert, G., Tack, R., Waegeman, D., Manicardi, A., & Madder, A. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad189 · Cited by 26
A perspective on the changing landscape of HTS
Lanne, A., Usselmann, L. E. J., Llowarch, P., Michaelides, I. N., Fillmore, M. C., & Holdgate, G. A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103670 · Cited by 20
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53
Klett, T., Schwer, M., Ernst, L. N., Engelhardt, M. U., Jaag, S., Masberg, B., Knappe, C., Lämmerhofer, M., Gehringer, M., & Boeckler, F. M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s466829 · Cited by 23
Concise Total Syntheses of ( − )-Crinipellins A and B Enabled by a Controlled Cargill Rearrangement
Xu, B., Zhang, Z., Tantillo, D. J., & Dai, M. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c07900 · Cited by 21
Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core
Xu, J., Ong, E. H., Hill, J., Chen, A., & Chai, C. L. L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.10.006 · Cited by 21
Development of benzo[1,4]oxazines as biofilm inhibitors and dispersal agents against Vibrio cholerae
Warner, C. J. A., Cheng, A. T.-A., Yildiz, F. H., & Linington, R. G. (2014) · Chemical Communications · doi:10.1039/c4cc07003h · Cited by 20
Reversible Ketomethylene-Based Inhibitors of Human Neutrophil Proteinase 3
Budnjo, A., Narawane, S., Grauffel, C., Schillinger, A.-S., Fossen, T., Reuter, N., & Haug, B. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500782s · Cited by 20
Substituted tetrazoles as multipurpose screening compounds
Rüger, N., Fassauer, G. M., Bock, C., Emmrich, T., Bodtke, A., & Link, A. (2016) · Molecular Diversity · doi:10.1007/s11030-016-9711-x · Cited by 20
Inhibition ofO-acetylserine sulfhydrylase by fluoroalanine derivatives
Franko, N., Grammatoglou, K., Campanini, B., Costantino, G., Jirgensons, A., & Mozzarelli, A. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1504040 · Cited by 21
Photogeneration of Quinone Methides as Latent Electrophiles for Lysine Targeting
Pérez–Ruíz, R., Molins‐Molina, O., Lence, E., González‐Bello, C., Miranda, M. A., & Jiménez, M. C. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.8b01559 · Cited by 22
2-Hydroxy-N-phenylbenzamides and Their Esters Inhibit Acetylcholinesterase and Butyrylcholinesterase
Krátký, M., Štěpánková, Š., Houngbedji, N.-H., Vosátka, R., Vorčáková, K., & Vinšová, J. (2019) · Biomolecules · doi:10.3390/biom9110698 · Cited by 22
“Based on t e changes of enzyme activity in the presence of tested i ibitor during prolonged incubation, i is possible to distinguish reversible, pseudo-irreversible and irreversible inhibition [35,36].”
BackgroundStructure-Based Design of Selective, Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors
Rowlands, R. A., Cato, M. C., Waldschmidt, H. V., Bouley, R. A., Chen, Q., Avramova, L. V., Larsen, S. D., Tesmer, J. J. G., & White, A. D. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00365 · Cited by 20
Design and Discovery of Covalent α-GalCer Derivatives as Potent CD1d Ligands
Kishi, J., Inuki, S., Kashiwabara, E., Suzuki, T., Dohmae, N., & Fujimoto, Y. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b00700 · Cited by 20
Molecular Interrogation to Crack the Case of O‐GlcNAc
Estevez, A., Zhu, D., Blankenship, C. M., & Jiang, J. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000155 · Cited by 23
Craven, G. B., Affron, D. P., Kösel, T., Wong, T. L., Jukes, Z., Liu, C., Morgan, R. M. L., Armstrong, A., & Mann, D. J. (2020) · ChemBioChem · doi:10.1002/cbic.202000457 · Cited by 21
Rational Tuning of Fluorobenzene Probes for Cysteine‐Selective Protein Modification
Embaby, A. M., Schoffelen, S., Kofoed, C., Meldal, M., & Diness, F. (2018) · Angewandte Chemie · doi:10.1002/ange.201712589 · Cited by 23
Subclass‐Specific Labeling of Protein‐Reactive Natural Products with Customized Nucleophilic Probes
Rudolf, G. C., Koch, M. F., Mandl, F. A. M., & Sieber, S. A. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201405009 · Cited by 20
Role of carfilzomib in the treatment of multiple myeloma
Khan, R. Z., & Badros, A. Z. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.26 · Cited by 20
Mechanism-Based and Computational-Driven Covalent Drug Design
Luo, Y. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01278 · Cited by 23
Wang, Y., Zhang, J., Xu, S., Li, J., Liu, W., Jiang, M., & Bai, G. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156807 · Cited by 21
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
Tang, M., Gong, M., Liu, X., Zhang, T., Liu, Z., & Song, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118106 · Cited by 23
Karageorgos, I. L., Wales, T. E., Janero, D. R., Zvonok, N., Vemuri, K. V., Engen, J. R., & Makriyannis, A. (2013) · Biochemistry · doi:10.1021/bi400430k · Cited by 19
Steadman, D., Atkinson, B. N., Zhao, Y., Willis, N. J., Frew, S., Monaghan, A. E., Patel, C., Armstrong, E., Costelloe, K., Magno, L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01735 · Cited by 19
CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery
Benns, H. J., Storch, M., Falco, J. A., Fisher, F. R., Tamaki, F. K., Alves, E., Wincott, C. J., Milne, R., Wiedemar, N., Craven, G. B., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01249-y · Cited by 19
“Donor repair templates were designed to (1) destroy the protospacer adjacent motif (PAM) and/or gRNA seed sequence required for Cas9 targeting and so prevent further modification of the site following integration; (2) provide a recodonized stretch of sequence proximal to the target cysteine for the generation of integ…”
BackgroundMethodInfluentialTargeting the I7L Protease: A Rational Design for Anti-Monkeypox Drugs?
Dodaro, A., Pavan, M., & Moro, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087119 · Cited by 20
“the initial hits into pharmacological tools with any real-world application [47], hence, the idea of performing a structure-based virtual screening for identifying noncovalent binders.”
BackgroundBhowmik, R., Kant, R., Manaithiya, A., Saluja, D., Vyas, B., Nath, R., Qureshi, K. A., Parkkila, S., & Aspatwar, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1265573 · Cited by 19
“However, not all medications attach non-covalently to the active site; other compounds, such as covalent drugs (Singh et al., 2011), bind covalently.”
BackgroundEvison, B. J., Actis, M. L., Wu, S. Z., Shao, Y., Heath, R. J., Yang, L., & Fujii, N. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.09.058 · Cited by 21
Exploration of Piperidinols as Potential Antitubercular Agents
Abuhammad, A., Fullam, E., Bhakta, S., Russell, A. J., Morris, G. M., Finn, P. W., & Sim, E. (2014) · Molecules · doi:10.3390/molecules191016274 · Cited by 19
Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket
Bai, Y., Xue, H., Wang, K., Cai, L., Qiu, J., Bi, S., Lai, L., Cheng, M., Liu, S., & Liu, K. (2012) · Amino Acids · doi:10.1007/s00726-012-1394-8 · Cited by 19
Kovalent‐allosterische Kinase‐Inhibitoren
Weisner, J., Gontla, R., Westhuizen, L. V. D., Oeck, S., Ketzer, J., Janning, P., Richters, A., Mühlenberg, T., Fang, Z., Taher, A., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201502142 · Cited by 19
Protective Properties of 2-Acetylcyclopentanone in a Mouse Model of Acetaminophen Hepatotoxicity
Zhang, L., Gavin, T., Geohagen, B. C., Liu, Q., Downey, K. J., & LoPachin, R. M. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.205435 · Cited by 19
Berneman, A., Montout, L., Goyard, S., Chamond, N., Cosson, A., D’Archivio, S., Gouault, N., Uriac, P., Blondel, A., & Minoprio, P. M. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060955 · Cited by 19
Nie, C., Li, S., Wang, B., Liu, L., Hu, R., Chen, H., Lv, F., Dai, Z. H., & Wang, S. (2016) · Advanced Materials · doi:10.1002/adma.201600106 · Cited by 19
Limitations of Ligand-Only Approaches for Predicting the Reactivity of Covalent Inhibitors
Voice, A. T., Tresadern, G., van Vlijmen, H., & Mulholland, A. J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00404 · Cited by 18
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.